Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer

Lester, J.; Dodwell, David; Purohit, O.P.; A. Gutcher, Sandra; P. Ellis, Susan; Thorpe, Ruth; Horsman, Janet; E. Brown, Janet; Hannon, R.A.; E. Coleman, Robert

doi:10.1158/1078-0432.ccr-07-5101

Public

Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer

Published in Clinical Cancer Research • Sep 30, 2008

Authors:

J. Lester

David Dodwell

O.P. Purohit

Abstract

PURPOSE: The aromatase inhibitor anastrozole is a highly effective well-tolerated treatment for postmenopausal endocrine-responsive breast cancer. However, its use is associated with accelerated bone loss and an increase in fracture risk. The ARIBON trial is a double-blind, randomized, placebo-contr...

Subject

Medicine

Anastrozole

Aromatase inhibitor

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!